1. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study

  2. Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations

  3. Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors

  4. Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer

  5. Evolving population-based statistics for rare epithelial ovarian cancers

  6. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma

  7. Intratumoral heterogeneity accounts for apparent progression of noninvasive serous tumors to invasive low-grade serous carcinoma:  a study of 30 low-grade serous tumors of the ovary in 18 patients associated with peritoneal carcinomatosis

  8. Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes

  9. Low-grade serous ovarian cancer: State of the science

  10. Low-grade serous ovarian carcinoma: Recommendation for efficient ancillary testing and standardized biomarker reporting from the Canadian LGSC community of practice

  11. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

  12. Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data

  13. Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum

  14. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: a nationwide study

  15. Significance of lymph node ratio on survival of women with borderline ovarian tumors

  16. The Role of GDF15 in Regulating the Canonical Pathways of the Tumor Microenvironment in Wild-Type p53 Ovarian Tumor and Its Response to Chemotherapy

  17. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance

Previous

2021
Next

2019